THE host does not appear to produce an immune reaction against a spontaneous tumour, or reacts too little and too late. If the host could be sensitised against its tumour a cure might result. The small lymphocyte is thought to play ani important role in some hypersensitivity reactions (Landsteiner and Chase, 1942) and in reactions against incompatible grafts (see Symposium edited by Medawar, 1963, and Gowans, 1965, for reviews). We therefore studied protection against fatal challenge with BP8 ascites tumour in C3H, or C3H/57 F1 mice, using lymphocytes from C57B1 mice donors, injected with BP8 cells. alone or with Freund's complete adjuvant. The F1 hybrid cross (C3H $ x C57B1 S) was used to avoid any rejection of the lymphocytes obtained from the " immunised " C57 donors. Later we found that pure C3H mice behaved like the C3H/C57 F1 for the purpose of the experiment.
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METHODS
The BP8 tumour was maintained by serial passage in C3H mice. After 12 days the mice were killed by cervical dislocation, 1 ml. of Hank's solution and 5 units heparin/ml. were injected i.p. and the ascitic fluid removed under sterile conditions. The cells were diluted with heparinised Hank's solution to an appropriate concentration after a viable count had been made with Trypan Blue.
Immunisation procedures.-BP8 cells were counted and then " killed " by rapid passage three times from liquid nitrogen to a 370 C. water bath. Phasecontrast microscopy confirmed that all cells were dead. An identical method was used for killing spleen and liver cells for Experiment 8.
Use of Freund's complete adjuvant (Difco).-In order to ensure intimate mixing (without heat) freeze/thawed BP8 cell suspensions were emulsified with Freund's adjuvant by repeated passage through 3 cm. of fine polythene tubing tightly fitting between two tuberculin syringes with Luer-locked needles.
The details of the immunisation schedules are found in Tables I, IV and X in conjunction with the appropriate experiments.
Preparation of lymphocytes from immuninsed (C57Bl mice (1) " Hash " preparations of lymphoid cells.-Lymph nodes or spleen were removed under sterile conditions, dissected free of fat, minced with angled scissors in a plastic or siliconised Petri dish and diluted with sterile Hanks' solution.
(2) Isolation from blood (modified from method of Skoog and Beck, 1956 ).-Blood from cardiac puncture was heparinised (20 units/ml.), diluted with twice * Gibb Fellow of the British Empire Cancer Campaign for Research. its volume of 400 Dextran 110 in saline, and left for 30 minutes at room temperature in a tube at an angle of 450, with frequent inversions. This treatment yielded the best size of rouleaux. The supernatant was filtered through 3 cm. of densely packed glass wool in a sterile, siliconised Pasteur pipette (to remove polymorphs and monocytes) and washed through with 3 to 4 ml. Hank's solution or TC 199. The filtrate was centrifuged at 500 g. for 5 minutes and resuspended in 1 ml. of Hank's solution or TC 199. Leishmann-stained smears showed that the white cells were almost 100% small lymphocytes with considerable red cell contamination.
(3) Isolation from spleen (based on Janowsky, Rosenau. and Moon, 1964).-Minced spleens from 2 mice were suspended in 5 ml. TC 199 and filtered through 2 layers of lint-free gauze. After centrifugation the packed cells were resuspended in 10 nil. of unbuffered 0-35 00 saline to lyse the erythrocytes. After 1 minute the salinity was restored by adding 1 2 ml. 500 saline. This process was repeated and finally the cell suspension was spun and resuspended three times in TC 199. A viable count showed that the lymphocytes survived this treatment very much better than macrophages.
(4) Isolation from lymph nodes.-Lymph nodes were disrupted by mincing anld pipetting in a little TC 199; the suspension was passed through a double layer of fine muslin gauze, spun and washed twice with TC 199, and adjusted . 228*, 228*, 228* * Experiment was terminated at 228 days, mice healthy and at autopsy no abnormalities were seen. Experiment 2.- (Table III) . When Experiment 1 was repeated very significant protection was given by lymph node and spleen hash made from C57 mice which had received 4 injections of freeze/thawed BP8 cells (Table I Table IV , Groups C and D. Various doses of lymphocytes prepared from spleen, or lymph nodes of these mice were used to protect C3H/C57 F1 mice or C3H mice against BPS cells. (Table V) . Protection by lymphocytes from C57 mice immunised with and without Freund's adjuvant (Table IV , Groups D and C respectively) were compared quantitatively. Group C lymphocytes showed no protection; group D lymphocytes showed slight protection at a dose of 2 x 105, and significant protection at 8 x 105 and 3 X 106. Survival times were significantly greater for animals treated with group D lymphocytes (" t " 5.4, n = 22, p < 0.001).
Experiment 4 (Table VI) . Lymphocytes prepared from spleens of mice immunised as in Table IV longer than the C3H/C57 F1 controls: nevertheless the results suggest that the frozen-stored lymphocytes had retained most of their activity. The survival after protection with 1-4 x 106 freshly isolated lymphocytes was much better than anticipated, possibly due to the use of C3H in lieu of C3H/C57 F1 mice, or because the C57 donors received a fifth immunisation dose.
Experiment 5.- (Table VII) . Lymphocytes from immunised C57 donors gave considerable protection when injected into C3H mice 24 hours after challenge by BP8 cells. However, protection appeared less complete than that given by fewer lymphocytes injected at the same time as the tumour cells, possibly because the tumour cells multiplied during the 24-hour delay and spread throughout the peritoneal cavity.
It was considered that control mice might survive longer if the exudation of ascitic fluid into the peritoneal cavity could be delayed. To test this, fluid intake was restricted just before and during the onset of ascites. The mean survival of the unprotected mice was increased from 15-2 to 19-25 days (" t "2.32, n = 7; p = 0.06). However, the mean survival of all 8 water-restricted controls (19.9 + 1-3 days) did not differ significantly from the mean of all 30 unprotected C3H controls (17.6 ± 0-5 days); "tt "-1-64, n = 36; 02-> p > 0 1. 14, 15, 15, 16, 16 16, 18, 19, 24 26, 208t, 208t, 208t, 208t 30, 34*, 68, 97, 208t 208t, 208t, 208t, 208t, 208t 16, 30, 30*, 51, 208t Five of the control mice and 5 of the experimental mice were fluid restricted on the 4th and 6th day after the first injection.
Water restriction increased slightly the survival time of the controls. Table IV , Group F.) (ii) "Protected " with 2-5 X 106 lymphocytes (from 0/5 13. 13, 13, 14, 14 normal C57BI mice) which had been incubated at 37°C. for 30 min. with 1 ml. of serum from C57Bl mice sensitised with 4 doses of BP8 cells + Freund's adjuvant (See Table IV , Group D) (iii) " Protected " with lymphoid preparations made from C57BI mice injected with 3 x 0.-1 ml. of Freuind's adjuvant alone (See Table IV (ii) Normal C57 lymphocytes, incubated with serum from C57 mice (immunised as in Table IV , Group D) and injected into C3H/C57 F1 mice, give no protection.
(iii) Hash preparations from C57 mice injected with Freund's adjuvant alone (Table IV , Group E) were injected into C3H/C57 F1 mice challenged with BP8 cells i.p.; although survival times were significantly longer than the control group, they were not significantly longer than the mean survival time of all the C3H/C57 F1 control groups. The protection afforded was not in the same order of magnitude as that given by lymphoid cell or lymphocyte preparations from C57 mice injected with both BP8 cells and Freund's adjuvant (see Experiments 1 to 5). 15, 16, 17, 21, 26 0/6 . 14, 14, 16, 17, 17, 17 1/5 . 16, 17, 17, 20, 23 0/6 . 11, 11, 12, 12, 13, 14 quickly than the controls. This early experiment, in collaboration with Professor R. R. A. Coombs, forced us to consider the possibility that if the outpouring of plasma into the peritoneal cavity could be delayed, then the animals own immune mechanisms would be given a better chance of dealing with the tumour cells. Experiment 10.- (Table XIII) . 8 C3H mice (immunised as in Table X , Groupings G and H) were challenged with 5 x 104 BP8 cells i.p., but fluid intake was restricted on the 3rd, 5th and 10th day. The C3H mice injected with BP8 cells alone survived slightly longer than expected, but those immunised with BP8 plus Freund's adjuvant showed definite protection. We have reason to believe that the BP8 tumour is isogeneic with C3H mice. It was induced by benzopyrene in this strain and as few as 100 cells are said to be 1000% lethal. We have not titrated it but we have used doses down to 6 x 103 with complete success; 5 X 104 cells was chosen as a big dose and was fatal in unprotected C3H/C57 F1 mice in under 20 days. We always challenged with freshly isolated cells to avoid the uncertainties involved in using cells stored in liquid nitrogen. However, both the tumour and the inbred mice can of course vary during repeated passage. Whenever possible the lymphocytes were isolated 7 days after the last immunising dose since lymphocyte immune-activity is maximal at this time whereas humoral-antibody titres are still low (Brondz, 1964) . This was the reason for our schedule of repeated injections in preparing the C57 lymphocyte donors. In order to avoid damaging their antigenic structure, BP8 cells were killed by freeze/thawing, and intimate mixing with Freund's adjuvant was aclhieved without heat development by the emulsification techniques we employed. Some difficulty was experienced in isolating lymphocytes from the small quantity of blood available from mice. Care was taken to use non-wettable plastic or siliconed-glass apparatus. Viable counts showed good recovery of lymphocytes, practically free from other white cells, but with some red cell contamination.
The mixing of living BP8 cells with lymphocyte preparations just before injection i.p. appeared to have no deleterious effect on the BP8 cells, since the challenged animals invariably died, unless the lymphocytes were from allogeneic, and adequately immunised donors. Also " competent " lymphocytes gave protection when injected 24 hours after the tumour dose. Kidd and Toolan (1950) found a marked inhibition of tumour growth when susceptible mice were injected with pre-incubated mixtures of lymphoma cells anid minced lymph niodes from mice with regressed lymphoma. However, Winn (1961) , using sarcoma (Sal), found that incubation of cell mixtures before injection into host mice had no effect on the level of activity observed and concluded that the two cell typ)es did not react in vitro. Indeed, the results obtained by Kidd and Toolan (1 95(i) could have been due to the activity of the lymphocytes in vivo.
The spleen and lymph node hash used in our preliminary experiments wvould have contained other cells besides lymphocytes. Bennett (1965) has shown specific suppression of tumour growth by isolated peritoneal macrophages from immunised mice, but these were less effective than the lymphocytes from the same peritoneal exudates. Also Gough, Elves and Israels (1965) have shown that macrophages can develop from lymphocytes in vitro (in the presence of polymorphs). Our experiments indicated that blood lymphocyte preparations had most anti-tumour activity, on a per-cell basis, and the number of macrophages in these preparations must have been very small. The evidence in favour of the lymphocyte being the cell involved, accumulated since the pioneer work of Landsteiner and Chase (1942), Billingham. Brent and Medawar (1954) (i) There is no evidence of any non-specific activity of allogeneic lymphocytes from non-immunised donor C57 mice against BP8 cells. We found no sign of runt disease in any long-term survivors, so we have no indication that allogeneic C57 donor lymphocytes acted against the host C3H/C57 F1 or C3H mice.
(ii) Bubenik and Koldovsky (1964) have shown that anti-tumour immunity can be transferred with serum, and Stuck. Boyse, Old and Carswell (1964) found cytophilic antibody present in several types of mouse leukaemia. However, we do not believe that humoral antibody or cytophilic antibody (Boyden, 1963) can explain the antitumour activity of our lymphocyte preparations because they were all well washed in TC 199 and the only possible transfer of y globulin would be that absorbed on to any red cells present. Also in experiment 6 (ii), 1 ml. of serum froin mice (whose lymphocytes gave good protection) gave no protection when incubated with normal lymphocytes and the combination was injected i.p. The findings of Algire, Weaver and Prehn (1957) , that homografts in millipore diffusion chambers survived if no cells could get through the pores, also discount the role of cytophilic antibody.
(iii) We obtained definite evidence (Experiments 1 and 5) that lymphocytes from C57 mice treated with BP8 cells plus Freund's adjuvant gave better antitumour protection than lymphocytes from mice immunised with BP8 cells alone. However, lymphocytes from mice injected with Freund's adjuvant alone (Experiment 6, iii) failed to give any long-term survivors. Thus Freund's adjuvant alone did not produce any useful non-specific enhancement of lymphocyte activity against H2 histocompatibility antigens on the BP8 cells.
(iv) It also seemed unlikely that BP8 cells were simply serving as a source of H2 histocompatibility antigens (Haughton, 1964) , since lymphocytes could not be sensitised by large doses of C3H spleen and liver cells plus Freund's adjuvant (Experiment 7). It is possible that we failed to sensitise the C57 mice to C3H spleen and liver cells even though we used large doses and these cells are known to " abound" in most of the important H2 histocompatibility antigens. It seems more likely that the BP8 cells have a tumour-specific antigen.
(v) (vi) (vii) (viii). Foley (1953), Prehn and Main (1957) , Prehn (1960) , Kleiin and Sjogren (1960) , Tuffrey and Batchelor (1964) , Moller (1964) and others have shown that chemically induced mouse tumours were capable of immunising isogeneic mice. Zilber and Gamaleya (1957) . using anaphylactic reactions, found evidence of tumour-specific antigens (see also Old and Boyse, 1964 , for a review of virus-induced tumours and specific antigens). If BP8 has a tumourspecific antigen then it should be possible to immunise C3H mice against it. We fail to show protection with lymphocytes from C3H donors which had beeil immunised with BP8 cells plus Freund's adjuvant (Experiment 8); and our first attempt to immunise C3H mice against direct challenge with living BP8 cells also failed (Experiment 9). However, the results of Experiment 10 were in favour of a tumour-specific antigen, since C3H mice injected with BP8 cells plus Freund's adjuvant could resist challenge with living BP8 cells if the formation of ascitic fluid was controlled by restriction of fluid intake. However, the tumour had been passaged for nearly 9 months and changes in the histocompatibility antigens could have occurred in tumour and host.
We think the activity of the sensitised small lymphocytes against the tumour cell merits further study, in particular with regard to the mechanisms by which the lymphocyte damages the tumour cell. With more knowledge it might be possible to use allogeneic, anti-tumour competent lymphocytes as a therapeutic agent in human cancer. SUMMARY C3H/C57 F1 mice or C3H mice were protected by lymplhocytes taken from (57 mice (injected with freeze/thawed BP8 cells plus Freund's complete adjuvant) against fatal challenge by living BP8 cells given i..p These lymphocytes would also protect if injected i.p. 24 lhours after the tumour cells.
In control experiments no protection was given by lymphocytes taken from non-immunised C57 mice, or those injected with C3H liver and spleen cells plus adjuvant, or adjuvant alone.
Some protection against challenge with BP8 cells was seen in C3H mice preimmunised with BP8 cells and Freund's adjuvant, but only when fluid intake was restricted about the time of the onset of ascites.
